Wordt geladen...
Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial
GD(2)-directed immunotherapies improve survival of high-risk neuroblastoma (NB) patients (pts). Treatment with chimeric anti-GD(2) antibodies (Ab), such as ch14.18, can induce development of human anti-chimeric Ab (HACA). Here, we report HACA effects on ch14.18/CHO pharmacokinetics, pharmacodynamics...
Bewaard in:
| Gepubliceerd in: | Cancers (Basel) |
|---|---|
| Hoofdauteurs: | , , , , , , , , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6210332/ https://ncbi.nlm.nih.gov/pubmed/30336605 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers10100387 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|